Free Trial
NASDAQ:SLRN

Acelyrin (SLRN) Stock Price, News & Analysis

Acelyrin logo
$2.10 -0.07 (-3.00%)
As of 10:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Acelyrin Stock (NASDAQ:SLRN)

Key Stats

Today's Range
$2.08
$2.14
50-Day Range
$2.08
$2.82
52-Week Range
$1.85
$7.25
Volume
79,738 shs
Average Volume
1.21 million shs
Market Capitalization
$212.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60
Consensus Rating
Hold

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Acelyrin Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

SLRN MarketRank™: 

Acelyrin scored higher than 68% of companies evaluated by MarketBeat, and ranked 403rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acelyrin has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Acelyrin has received no research coverage in the past 90 days.

  • Read more about Acelyrin's stock forecast and price target.
  • Earnings Growth

    Earnings for Acelyrin are expected to grow in the coming year, from ($2.53) to ($2.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acelyrin is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acelyrin is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acelyrin has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Acelyrin's valuation and earnings.
  • Percentage of Shares Shorted

    4.99% of the float of Acelyrin has been sold short.
  • Short Interest Ratio / Days to Cover

    Acelyrin has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acelyrin has recently decreased by 22.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Acelyrin does not currently pay a dividend.

  • Dividend Growth

    Acelyrin does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.99% of the float of Acelyrin has been sold short.
  • Short Interest Ratio / Days to Cover

    Acelyrin has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acelyrin has recently decreased by 22.01%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Acelyrin has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Acelyrin this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Acelyrin insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,003.00 in company stock.

  • Percentage Held by Insiders

    13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acelyrin's insider trading history.
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

SLRN Stock News Headlines

Alumis and ACELYRIN Announce Amended Merger Agreement
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
See More Headlines

SLRN Stock Analysis - Frequently Asked Questions

Acelyrin's stock was trading at $3.14 at the beginning of the year. Since then, SLRN shares have decreased by 33.0% and is now trading at $2.1050.
View the best growth stocks for 2025 here
.

Acelyrin, Inc. (NASDAQ:SLRN) released its quarterly earnings results on Wednesday, March, 19th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.07.

Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Top institutional shareholders of Acelyrin include Rhumbline Advisers (0.10%) and Western Wealth Management LLC (0.02%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Mina Kim, Daniel J Becker and Ronald Oyston.
View institutional ownership trends
.

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

Last Earnings
3/19/2025
Today
4/24/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLRN
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.60
High Stock Price Target
$20.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+342.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-381,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.74 per share
Price / Book
0.32

Miscellaneous

Free Float
86,682,000
Market Cap
$218.97 million
Optionable
Optionable
Beta
1.12
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:SLRN) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners